Sylvie Grégoire, Member of the Board, Member of the Audit Committee, Member of the Nomination Committee, Member of the R&D Committee

  • Executive chair of the board of EIP Pharma, Inc.
  • Member of the board of Perkin Elmer Inc.
  • Member of the board of F2G Ltd.

  • President of Human Genetic Therapies Shire PLC, 2007-2013.
  • Executive chair of IDM Pharma Inc., 2006-2007.
  • President and chief executive officer in GlycoFi Inc., 2003-2004. 

  • Considered independent under the Danish Recommendations on Corporate Governance.
  • Member of the Board of Directors since March 2015. Most recently elected in 2021 for a term of one year.
  • Member of the Audit Committee since March 2015. The Board has assessed that Ms Grégoire qualifies as independent pursuant to the US Securities Exchange Act.
  • Member of the Research & Development Committee since March 2017.
  • Member of the Nomination Committee since March 2018.

  • Global corporate leadership
  • Healthcare and pharma industry
  • Medicine & science
  • Finance & accounting
  • Business development, M&A and external innovation sourcing
  • Human capital management

  • 1986: Pharmacy Doctorate degree, the State University of NY at Buffalo, US,
  • 1984: BA in Pharmacy, Laval University, Canada.
  • 1980: Science College degree, Séminaire de Sherbrooke, Canada.

Canadian and US national, born 1961. Female.